Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Calcifediol Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 8/20 | 0.82 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | SREBF1 | P36956 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.82 |
| ▸ | PGR | P06401 | 2/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.82 |
| ▸ | CDC25A | P30304 | 1/20 | 0.82 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.82 |
| ▸ | HPGD | P15428 | 1/20 | 0.82 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.82 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.82 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.82 |
| ▸ | DRD3 | P35462 | 1/20 | 0.82 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calcifediol Anhydrous SCHEMBL10018928 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL13301741 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL9933434 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL3296 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL24102681 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL5614025 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL24051907 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL14112503 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL24571935 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL22403256 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3152185-B1 | METHOD AND USAGE OF A SALT FOR SEPARATING EPIMERS BY ION MOBILITY SPECTROMETRY | ROCHE DIAGNOSTICS GMBH (DE) | 2023-10-04 | — | — | EP | claimed |
| CN-116482241-A | Liquid chromatography-mass spectrometry combined method and kit for detecting metabolites of vitamin D | 广州凯普医药科技有限公司 | 2023-07-25 | — | — | CN | claimed |
| WO-2008154574-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF CARDIAC HYPERTROPHY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080305186-A1 | Method and Composition for the Treatment of Cardiac Hypertrophy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-12-11 | — | — | US | claimed |
| US-12459905-B2 | Reagent for mass spectrometry | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4623304-A1 | DERIVATISATION AGENT FOR LASER DESORPTION IONIZATION MASS SPECTROMETRY | F. Hoffmann-La Roche AG (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-20250277801-A1 | DERIVATISATION AGENT FOR LASER DESORPTION IONIZATION MASS SPECTROMETRY | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-2249842-B2 | USE OF 25-HYDROXY-VITAMIN D3 AND VITAMIN D TO AFFECT HUMAN MUSCLE PHYSIOLOGY | DSM IP ASSETS BV (NL) | 2025-03-05 | — | — | EP | disclosed |
| US-20250064735-A1 | CONTAINER SYSTEM AND PHARMACEUTICAL FOAM COMPOSITION COMPRISING BETAMETHASONE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2025-02-27 | — | — | US | disclosed |
| WO-2024110385-A1 | DERIVATISATION AGENT FOR LASER DESORPTION IONIZATION MASS SPECTROMETRY | F. HOFFMANN-LA ROCHE AG (CH) | 2024-05-30 | — | — | WO | disclosed |
| US-20240092742-A1 | REAGENT FOR MASS SPECTROMETRY | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-11885818-B2 | Reagent for mass spectrometry | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20010036472-A1 | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings | ENCINAL PHARMACEUTICAL INVESTMENTS, LLC | 2001-11-01 | — | — | US | disclosed |
| EP-1140012-A2 | CONVERSION OF LIQUID FILLED GELATIN CAPSULES INTO CONTROLLED RELEASE SYSTEMS BY MULTIPLE COATINGS | Alza Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038650-A1 | GASTRIC RETENTION DOSAGE FORM HAVING MULTIPLE LAYERS | ALZA CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000035419-A2 | CONVERSION OF LIQUID FILLED GELATIN CAPSULES INTO CONTROLLED RELEASE SYSTEMS BY MULTIPLE COATINGS | ALZA CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
| EP-0981615-A1 | PROTEIN KINASE C INHIBITOR-LIKE PROTEIN (IPKC-2) | INCYTE PHARMACEUTICALS, INC. (US) | 2000-03-01 | — | — | EP | disclosed |
| US-6015678-A | CONTACTING THE NUCLEIC ACIDS OF A SAMPLE WITH A NUCLEOTIDE SEQUENCE COMPLEMENTARY TO THE INHIBITOR, DETECTING HYBRIDIZATION; DIAGNOSIS OF CANCER, AUTOIMMUNE DISORDERS OR COGNITIVE DISORDERS | INCYTE PHARMACEUTICALS, INC. (US) | 2000-01-18 | — | — | US | disclosed |
| US-5922571-A | HYBRIDIZED DETECTOR | INCYTE PHARMACEUTICALS, INC. (US) | 1999-07-13 | — | — | US | disclosed |
| WO-1998039444-A1 | PROTEIN KINASE C INHIBITOR-LIKE PROTEIN (IPKC-2) | INCYTE PHARMACEUTICALS, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459905-B2 | Reagent for mass spectrometry | SRMS, PTMS, MMAB | VDR 4478/4885MAPT 3790/4885SMN1; SMN2 1851/4885 |
| US-20250064735-A1 | CONTAINER SYSTEM AND PHARMACEUTICAL FOAM COMPOSITION COMPRISING BETAMETHASONE | CYP24A1, CYP2R1, VDR | VDR 3/4885MAPT 1367/4885SMN1; SMN2 4785/4885 |
| US-20240092742-A1 | REAGENT FOR MASS SPECTROMETRY | SRMS, PTMS, MMAB | VDR 4478/4885MAPT 3790/4885SMN1; SMN2 1851/4885 |
| US-11885818-B2 | Reagent for mass spectrometry | SRMS, PTMS, MMAB | VDR 4478/4885MAPT 3790/4885SMN1; SMN2 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.